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Numerous studies have shown that statin therapy initiated early after heart transplantation has 
beneficial effects on the development of cardiac allograft vasculopathy. Recently, we were able to 
show in a randomized clinical trial that simvastatin treatment of brain-dead donors conditions the 
heart transplant to withstand ischemia-reperfusion injury and to reduce the need for rejection 
treatments early after transplantation. In this study, we analyzed myocardial gene expression profiles 




84 heart transplant donors received 80 mg of simvastatin via nasogastric tube (n=42), or no 
treatment (n=42) in a prospective, double-blinded randomized controlled trial. Transmural Tru-Cut 
biopsies were taken from the apex of left ventricle of the donor heart immediately before reperfusion 
and 1 hour after reperfusion. 20 heart biopsies from donors without treatment and 20 heart biopsies 




The preliminary analysis of RNA sequencing data from myocardial biopsies revealed altogether 137 
significantly differentially expressed genes in all pairwise comparisons.  The overall biological 
functions of these genes were related to gene ontology terms such as response to toxic substance, 
leukocyte migration, neutrophil mediated immunity, response to lipopolysaccharide, and response 
to oxidative stress. At the KEGG pathway level, our results indicated alterations in IL-17, TNF, MAPK 




We have shown in previous studies that donor simvastatin treatment induces protective effects 
against IRI in heart transplant recipients. In this study, we were able to detect significantly 
differentially expressed genes related to effects of simvastatin treatment. In order to single out genes 
that show beneficial effects of simvastatin treatment, further analysis will be conducted by exploring 
gene expression changes in specific biological functional categories, such as interleukin signaling 
and neutrophil degranulation. The complete analysis will be presented at the ISHLT 2019 congress. 
